In a highly regulated environment like Teva Pharmaceutical Industries, adaptability and flexibility are critical, particularly during crises. The best response demonstrates a balance between decisive action, adherence to established protocols, transparent communication, and a focus on patient safety. The most effective approach involves immediately activating the pre-defined crisis management plan, which outlines specific steps and responsibilities. Simultaneously, communicating transparently with relevant stakeholders (employees, regulatory bodies, patients, and the public) is crucial to maintain trust and manage expectations. Prioritizing patient safety above all else ensures that any actions taken minimize potential harm. While individual initiative is valuable, deviating from established protocols without proper authorization can create further complications and potential regulatory issues. A collaborative approach, involving key decision-makers and subject matter experts, ensures that all aspects of the crisis are considered and addressed effectively. Delaying communication or solely relying on personal judgment can exacerbate the situation and erode stakeholder confidence. The best approach integrates protocol adherence, transparent communication, patient safety prioritization, and collaborative decision-making.

The most effective approach involves a combination of clear communication, collaborative problem-solving, and proactive leadership. The situation necessitates a shift in project direction due to unforeseen regulatory changes. Immediately informing the team about the updated regulatory landscape demonstrates transparency and builds trust. Actively soliciting input from team members leverages their expertise and fosters a sense of ownership in the revised strategy. Framing the challenge as an opportunity for innovation encourages creative problem-solving and helps the team adapt to the new circumstances. Providing the team with necessary resources, such as training on the new regulations, empowers them to effectively contribute to the project’s success. Furthermore, closely monitoring the project’s progress and providing regular feedback ensures alignment with the revised objectives and allows for timely adjustments. This approach acknowledges the uncertainty, promotes teamwork, and maintains project momentum while adhering to the changing regulatory requirements, all essential components of effective leadership and adaptability within Teva Pharmaceutical Industries.

In a fast-evolving pharmaceutical landscape, Teva’s success hinges on its ability to adapt quickly and effectively. Consider the scenario where a new regulatory guideline dramatically alters the production process for a key generic drug, impacting timelines and budgets. The ideal response involves quickly assessing the impact, revising project plans, communicating transparently with stakeholders (including potentially impacted clients), and exploring alternative production strategies or process adjustments to mitigate delays while maintaining compliance. This requires not only understanding the regulatory change itself but also the interconnectedness of various departments within Teva (manufacturing, regulatory affairs, supply chain, commercial) and the ability to influence them towards a revised course of action. A suboptimal response would focus solely on individual task completion without considering the broader implications, rigidly adhering to the original plan despite its infeasibility, or failing to communicate proactively with relevant parties. The critical element is demonstrating the ability to pivot strategically, maintain effectiveness under pressure, and communicate clearly across different functions to minimize disruption and uphold Teva’s commitment to delivering medications to patients. This also includes showing initiative in identifying potential solutions and advocating for their implementation, reflecting Teva’s value of proactive problem-solving.

In a rapidly evolving pharmaceutical landscape, adaptability and strategic leadership are crucial for navigating unforeseen challenges and capitalizing on emerging opportunities. A leader who can effectively adjust strategies, motivate teams, and foster collaboration is essential for sustaining growth and maintaining a competitive edge. In a crisis scenario, a leader’s ability to make quick, informed decisions, communicate transparently, and prioritize effectively can significantly impact the organization’s resilience and long-term success. Prioritizing employee well-being and fostering a culture of open communication are vital for maintaining morale and productivity during turbulent times. Effective delegation, coupled with clear expectations and constructive feedback, empowers team members and promotes ownership, contributing to a more agile and responsive organization. A leader’s capacity to inspire confidence and guide the team through uncertainty is paramount for ensuring stability and driving innovation.

In a rapidly evolving pharmaceutical landscape, Teva frequently undergoes strategic shifts, necessitating adaptability from its employees. The most effective response in this scenario balances immediate task completion with a proactive approach to understanding the broader organizational changes. Completing the urgent report demonstrates responsibility and commitment to current priorities. However, solely focusing on this without understanding the strategic shift could lead to the report becoming irrelevant or misaligned with the company’s new direction. Therefore, the ideal approach involves completing the report efficiently while simultaneously seeking information about the strategic shift. This demonstrates both responsiveness to immediate needs and a proactive commitment to adapting to change. It shows an understanding that individual tasks are interconnected with the overall strategic goals of the company. This approach ensures that the work is not only completed on time but also contributes effectively to Teva’s evolving objectives. Ignoring the strategic shift altogether or delaying the report to focus solely on understanding the shift would be less effective. Teva values employees who can balance immediate responsibilities with a broader understanding of the company’s strategic direction.

Long-term planning requires strategic thinking, an understanding of future trends, and the ability to set ambitious yet achievable goals. A long-term career vision provides direction and motivation, while a connection to the company’s mission fosters a sense of purpose. Demonstrating an interest in advancement within the organization and a willingness to take on new challenges are indicators of organizational commitment. Identifying factors that contribute to retention and actively seeking opportunities for internal mobility can enhance career satisfaction and contribute to the company’s success.

In a rapidly evolving pharmaceutical landscape, Teva emphasizes adaptability and leadership. A scenario requiring a pivot from a previously defined strategy tests these crucial competencies. The most effective response demonstrates an understanding of the initial strategic goals, an ability to recognize the need for a change in direction based on new data (regulatory hurdles and market shifts), and leadership in communicating this change and motivating the team towards the revised objective. Maintaining open communication, acknowledging the initial plan’s limitations, and clearly articulating the new strategic direction are vital. Furthermore, the response should emphasize collaborative problem-solving to navigate unforeseen challenges and capitalize on emerging opportunities within the evolving market. It’s important to demonstrate a data-driven approach to decision-making, incorporating regulatory insights and market analysis to inform the revised strategy. The best approach will not only address the immediate problem but also build resilience and adaptability within the team for future uncertainties. An effective leader will also acknowledge the impact of the change on the team, providing support and resources to ensure a smooth transition.

In a rapidly evolving pharmaceutical landscape, adaptability and flexibility are critical, particularly in roles requiring cross-functional collaboration and strategic vision. A project manager must be able to adjust plans, motivate the team, and maintain effectiveness amidst changing priorities, ambiguous situations, and unexpected transitions. This includes not only adjusting timelines and resource allocation but also re-evaluating the project’s strategic alignment with the company’s goals in light of new market data or regulatory changes. Leadership potential is demonstrated by the ability to set clear expectations, delegate effectively, provide constructive feedback, and resolve conflicts, all while communicating a strategic vision that aligns with Teva’s values and business objectives.

Moreover, the ability to pivot strategies when needed and remain open to new methodologies is essential. This requires a proactive approach to problem-solving, identifying potential risks and opportunities, and implementing creative solutions. The project manager should be able to analyze complex issues systematically, identify root causes, and make data-driven decisions, even under pressure. This involves not only technical skills but also the ability to navigate team dynamics, build consensus, and support colleagues in a collaborative environment. Effective communication is crucial, including verbal articulation, written clarity, presentation abilities, and active listening skills. The ability to manage difficult conversations and provide constructive feedback is also vital for fostering a positive and productive team environment.

In a rapidly evolving pharmaceutical landscape, particularly within a company like Teva, adaptability and strategic communication are paramount. Consider a scenario where a new regulatory guideline significantly impacts the production process of a key generic drug. The most effective response involves a multi-faceted approach. Firstly, promptly understanding the new regulation and its implications is crucial. This necessitates a deep dive into the specifics of the guideline and how it affects Teva’s existing procedures. Secondly, clear and concise communication is vital. This includes informing the relevant teams (production, regulatory affairs, quality control) about the changes, explaining the rationale behind them, and outlining the necessary adjustments. This communication should be tailored to each team’s specific needs and responsibilities. Thirdly, a revised action plan must be developed collaboratively. This plan should detail the steps required to comply with the new regulation, including modifications to production processes, documentation updates, and employee training. Furthermore, the plan should incorporate contingency measures to address potential challenges and delays. Finally, proactively engaging with regulatory bodies demonstrates Teva’s commitment to compliance and facilitates a smoother transition. This might involve seeking clarification on specific aspects of the regulation or providing updates on Teva’s progress in implementing the necessary changes. The effectiveness hinges on clear communication, collaborative planning, and proactive engagement with regulatory bodies, reflecting Teva’s values of integrity and patient safety.

In a rapidly evolving pharmaceutical landscape, particularly within a company like Teva, which operates globally and across diverse therapeutic areas, adaptability is crucial. The scenario highlights a situation where a team lead, Javier, faces conflicting priorities due to unexpected regulatory changes and shifting market demands. Effective leadership requires the ability to re-evaluate existing plans, communicate changes transparently, and motivate the team to embrace new strategies. Delegating tasks effectively ensures workload distribution and leverages team members’ strengths. Clear communication about the rationale behind the changes helps maintain morale and fosters understanding. Providing constructive feedback supports individual growth and improves overall team performance. A leader’s capacity to make decisions under pressure and resolve conflicts efficiently is essential for navigating complex situations and maintaining productivity. The best course of action is to proactively address the situation by reassessing project timelines, reallocating resources, and clearly communicating the updated priorities and expectations to the team, while also providing support and addressing any concerns. This approach demonstrates adaptability, decisive leadership, and effective communication, which are all vital for success in a dynamic pharmaceutical environment. It also allows for the identification of potential roadblocks and proactive mitigation strategies.

Understanding the competitive landscape involves analyzing competitor strategies, identifying market trends, and assessing the strengths and weaknesses of Teva’s competitors. Monitoring competitor product pipelines, pricing strategies, and marketing campaigns is essential for making informed business decisions. Ignoring the competitive landscape can lead to missed opportunities and strategic disadvantages. A strong understanding of the competitive landscape is essential for driving Teva’s success in the pharmaceutical industry.

In the pharmaceutical industry, and especially within a company like Teva that emphasizes both innovation and efficiency, project management skills are vital. When managing a project with a fixed deadline and budget, but encountering unforeseen technical challenges, a project manager needs to prioritize tasks that are most critical to meeting the project’s core objectives. While exploring innovative solutions is valuable, it shouldn’t jeopardize the project’s timeline or budget if it’s not essential for the project’s success. Similarly, while thoroughly documenting the challenges is important for future reference, it shouldn’t take precedence over addressing the immediate obstacles. Renegotiating the project scope to focus on the core deliverables is the most effective approach, as it allows the project team to deliver a valuable outcome within the given constraints. This may involve deferring less critical features or functionalities to a later phase. This approach aligns with Teva’s focus on delivering results and its commitment to efficient resource utilization.

The most effective approach in this scenario necessitates a leader who can adapt to the unexpected product recall while maintaining team morale and productivity. The initial reaction of panic and blame-shifting is a common response to crisis, indicating a need for immediate and decisive leadership. The leader should first acknowledge the situation and its potential impact, then shift the focus towards understanding the root cause and implementing solutions. This involves gathering accurate information, facilitating open communication to address concerns, and clearly defining revised priorities. It is essential to re-allocate resources effectively, possibly delaying less critical projects, to address the recall urgently. Moreover, the leader must foster a collaborative environment where team members feel safe to contribute ideas and support each other. By demonstrating composure, providing clear direction, and emphasizing the importance of learning from the experience, the leader can mitigate the negative impact of the recall and strengthen the team’s resilience. The leader must communicate transparently with the client, setting realistic expectations and demonstrating a commitment to resolving the issue. This approach showcases adaptability, leadership potential, teamwork, and strong communication skills, all crucial for navigating challenging situations within Teva Pharmaceutical Industries.

Initiative and self-motivation are highly valued at Teva, where employees are expected to take ownership of their work and proactively identify opportunities for improvement. Consider a scenario where a Teva regulatory affairs specialist, Ben, notices a discrepancy in the company’s database of approved drug labels. The discrepancy could potentially lead to compliance issues and regulatory penalties.

The most effective approach would involve Ben taking the initiative to investigate the discrepancy, identify the root cause, and propose a solution to correct the error and prevent future occurrences. He would need to review the relevant regulations, consult with colleagues, and analyze the data to determine the scope of the problem. He would then need to develop a plan to update the database, implement quality control measures, and train employees on proper labeling procedures.

This approach demonstrates initiative and self-motivation by proactively identifying and addressing a potential problem. It also reflects Teva’s commitment to regulatory compliance and its dedication to maintaining the highest standards of quality. A less effective approach would be to ignore the discrepancy, assume that it is not a significant issue, or wait for someone else to address it.

In a highly regulated environment like the pharmaceutical industry, and specifically within Teva, the ability to adapt and be flexible while also demonstrating leadership potential is critical, especially when dealing with ethical dilemmas. The scenario presented requires balancing competing priorities: maintaining compliance, addressing a potential ethical violation, and minimizing disruption to ongoing clinical trials. The most appropriate course of action involves immediately reporting the potential violation to the compliance department. This aligns with Teva’s commitment to ethical conduct and adherence to regulatory standards. Simultaneously, it’s crucial to assess the potential impact on the clinical trial. Depending on the severity and nature of the violation, a temporary pause may be necessary to ensure data integrity and patient safety. Communicating transparently with the clinical trial team and stakeholders is essential to manage expectations and minimize disruption. Ignoring the violation or attempting to resolve it internally without involving compliance could lead to significant legal and reputational risks for Teva. While efficiency and minimizing disruption are important, they cannot supersede ethical considerations and regulatory compliance. The ethical and regulatory implications of not addressing a potential violation outweigh the potential benefits of maintaining the current timeline. This approach demonstrates leadership by prioritizing ethical conduct and compliance while also taking responsible steps to mitigate the impact on the clinical trial. This is important as it highlights the candidate’s understanding of the critical balance between operational efficiency and ethical responsibilities within a highly regulated pharmaceutical environment.

In a rapidly evolving pharmaceutical landscape, Teva’s success hinges on its employees’ ability to adapt to changing priorities, embrace new methodologies, and maintain effectiveness during transitions. A candidate demonstrating strong adaptability will proactively seek to understand the reasons behind changes, quickly learn new processes or technologies, and effectively communicate these changes to their team. They would also be comfortable pivoting strategies when initial approaches prove ineffective, demonstrating resilience and a commitment to achieving desired outcomes. The most effective response showcases a proactive approach to understanding and implementing change, coupled with clear communication and a focus on maintaining team effectiveness during periods of transition. This adaptability ensures minimal disruption and maximizes productivity. Teva, as a global leader, requires employees who can navigate complex regulatory landscapes, adapt to diverse cultural norms, and embrace technological advancements. A candidate demonstrating adaptability is more likely to thrive in this dynamic environment and contribute to Teva’s continued success. The candidate should demonstrate an ability to quickly learn and apply new information.

The scenario describes a situation where a new biosimilar product is being launched by Teva, directly competing with an established biologic. A successful launch requires a multi-faceted approach considering regulatory compliance, market dynamics, and ethical considerations. A cross-functional team needs to collaborate effectively, and the sales team must be equipped with the necessary information and training to address physician concerns and promote the biosimilar responsibly. Maintaining open communication channels between departments ensures alignment on key messages and strategies. It also requires understanding of the regulatory pathways of biosimilars, and the nuances of interchangeability and substitution. A phased launch strategy, starting with regions receptive to biosimilars, allows for gathering data and refining the approach before a broader rollout. This also allows for a proactive management of potential negative perceptions and fostering confidence in the biosimilar’s efficacy and safety. Building strong relationships with key opinion leaders and patient advocacy groups can further enhance the biosimilar’s acceptance and uptake. Understanding the competitor’s strategies and anticipating their responses is crucial for maintaining a competitive edge. The team needs to be prepared to address any potential challenges related to pricing, reimbursement, and market access. Continuous monitoring of market trends and patient feedback enables the team to adapt their strategies and optimize the launch performance.

The most effective approach involves a blend of adaptability, leadership, teamwork, and communication. Prioritizing open communication ensures that all team members understand the rationale behind the shift and their new roles. Adjusting project timelines requires adaptability and a clear understanding of task dependencies. Redistributing tasks fairly and based on individual strengths leverages teamwork and optimizes efficiency. Setting clear expectations for the revised project plan and providing ongoing support demonstrates strong leadership. Documenting the changes and communicating them to all stakeholders ensures transparency and minimizes confusion. Ignoring the shift in strategy and continuing with the original plan is detrimental to project success and demonstrates a lack of adaptability. Solely focusing on individual tasks without considering the impact on the overall project hinders teamwork and can lead to misalignment. Micromanaging team members can stifle creativity and reduce motivation, ultimately impacting productivity. This scenario tests the candidate’s ability to navigate change, lead a team effectively, and maintain project momentum in a dynamic environment, all crucial skills within Teva’s fast-paced pharmaceutical setting. The candidate must understand how to balance individual contributions with overall team goals and how to communicate effectively to maintain alignment and motivation.

In a rapidly evolving pharmaceutical landscape, Teva emphasizes adaptability and leadership. The core of this scenario lies in the ability to quickly reassess strategies, motivate a team amidst uncertainty, and make decisive choices that align with both ethical considerations and business needs. The most effective response involves acknowledging the initial plan’s inadequacy, engaging the team in collaborative problem-solving to identify a viable alternative, and proactively communicating the revised strategy to stakeholders. This demonstrates adaptability, leadership, teamwork, and communication skills – all critical for success at Teva. Simply maintaining the original plan or solely focusing on individual solutions neglects the collaborative and communicative aspects vital for Teva’s operational model. Moreover, ignoring ethical considerations and potential risks could lead to severe compliance issues, a significant concern in the pharmaceutical industry. A leader at Teva must be able to inspire confidence, even when pivoting under pressure, ensuring the team remains productive and focused on delivering results while upholding the company’s values and regulatory obligations. The ability to re-evaluate, re-strategize, and re-communicate is key to navigating challenges and achieving success in a dynamic environment.

Long-term strategic planning is essential for a pharmaceutical company to maintain its competitive edge and achieve sustainable growth. This scenario tests a candidate’s ability to think strategically, anticipate future trends, and develop long-range plans. The best response demonstrates the ability to analyze market trends, identify opportunities and threats, and develop a strategic plan that aligns with the company’s mission and values. This involves considering factors such as regulatory changes, technological advancements, and competitive dynamics. A less effective response would involve failing to consider long-term implications, neglecting to analyze market trends, or developing a strategic plan that is not aligned with the company’s mission and values. The ideal response reflects Teva’s values of strategic thinking, innovation, and long-term sustainability, demonstrating the candidate’s ability to contribute to the company’s long-term success.

Effective communication is crucial in a global organization like Teva, especially when conveying technical information to non-technical stakeholders. It is not sufficient to simply present the data without context or explanation. The goal is to ensure that the stakeholders understand the key findings and their implications for the business. Using technical jargon without explanation can alienate the audience and hinder their ability to make informed decisions. Instead, translate the technical information into clear, concise language that is easily understandable. Provide context by explaining the purpose of the analysis, the methodology used, and the key assumptions made. Use visuals, such as charts and graphs, to illustrate the data and make it more accessible. Focus on the key takeaways and their relevance to the stakeholders’ roles and responsibilities. Encourage questions and provide clear, straightforward answers. By effectively communicating technical information, you can empower stakeholders to make informed decisions and contribute to the success of the organization.

In a rapidly evolving pharmaceutical landscape, Teva emphasizes adaptability, leadership, teamwork, communication, and problem-solving. Consider a scenario where a cross-functional team is tasked with launching a new generic drug in a market with fluctuating regulatory requirements. The team faces unexpected delays in obtaining necessary approvals due to evolving local interpretations of international guidelines. Simultaneously, a competitor launches a similar product with a slightly different formulation, creating pricing pressure. The team leader must navigate these challenges by re-prioritizing tasks, re-allocating resources, and communicating effectively with both internal stakeholders and external regulatory bodies. Effective leadership involves motivating the team amidst uncertainty, fostering collaboration to identify innovative solutions, and making informed decisions under pressure. Adaptability requires the team to adjust its launch strategy, potentially focusing on alternative markets or reformulating the drug to differentiate it from the competitor’s product. Problem-solving involves analyzing the root causes of the regulatory delays and developing strategies to expedite the approval process. Communication is vital for keeping all stakeholders informed of the evolving situation and ensuring alignment on the revised launch plan. The best approach demonstrates adaptability, strong leadership, effective teamwork, clear communication, and proactive problem-solving to mitigate the impact of the challenges and ensure a successful product launch. A leader who can effectively balance these competencies is most likely to succeed in such a dynamic environment.

The most effective approach in this scenario necessitates a balanced strategy that prioritizes patient safety and regulatory compliance while addressing the immediate supply chain disruption. Initiating a thorough risk assessment is paramount to evaluate the potential impact of using alternative suppliers on product quality and patient health. This assessment must adhere to stringent regulatory guidelines, such as those established by the FDA or EMA, and consider factors like supplier qualifications, manufacturing processes, and testing protocols. Simultaneously, transparent communication with regulatory bodies is crucial to inform them of the situation and seek guidance on navigating the supply chain challenges. Internally, cross-functional collaboration between supply chain, quality assurance, and regulatory affairs teams is essential to ensure a coordinated response. This includes exploring options such as expedited supplier qualification processes, enhanced testing of incoming materials, and potential product recalls if necessary. Furthermore, proactive communication with healthcare providers and patients is vital to manage expectations and provide timely updates on product availability. This comprehensive approach ensures that patient safety remains the top priority while mitigating the impact of the supply chain disruption. A reactive or siloed approach could lead to regulatory violations, compromised product quality, and potential harm to patients, ultimately damaging Teva’s reputation and long-term sustainability. The company’s values of integrity, patient focus, and collaboration should guide all decision-making during this crisis.

In a rapidly evolving pharmaceutical landscape, particularly within a generics-focused company like Teva, adaptability and strategic pivoting are crucial for success. The scenario presented requires evaluating how a candidate balances long-term strategic goals with immediate market pressures and regulatory shifts. Maintaining open communication channels ensures that leadership remains informed about ground-level realities, preventing strategic misalignment. Prioritizing flexibility in resource allocation enables quick responses to emerging opportunities or threats. The most effective approach involves a blend of proactive scenario planning, continuous market monitoring, and empowering teams to adapt their strategies within established guidelines. This ensures both responsiveness and adherence to overarching company objectives and regulatory requirements. The scenario underscores the importance of leadership in fostering a culture of adaptability while maintaining strategic direction, critical for navigating the complexities of the pharmaceutical industry. This includes being able to handle unexpected challenges, such as supply chain disruptions or sudden regulatory changes, which directly impact Teva’s ability to deliver medications to patients.

The most appropriate response aligns with ethical principles, regulatory guidelines, and Teva’s commitment to patient safety. Upon discovering that a colleague is falsifying data, the first and foremost responsibility is to ensure the integrity of the data and protect patient well-being. This requires taking immediate action to report the misconduct to the appropriate authorities within Teva, such as the compliance department or a designated ethics officer. It is crucial to document the observed instances of data falsification, including dates, times, specific data points, and any other relevant information. Reporting the misconduct internally allows Teva to investigate the matter thoroughly and take corrective action to prevent further data manipulation. While it may be tempting to confront the colleague directly or ignore the situation, these actions could compromise the investigation or enable the misconduct to continue. Maintaining confidentiality is important to protect the integrity of the investigation, but it should not supersede the obligation to report potential ethical violations. This approach demonstrates a commitment to ethical conduct, regulatory compliance, and patient safety, all of which are core values at Teva.

Effective communication within Teva Pharmaceuticals requires clarity, accuracy, and sensitivity, especially when conveying technical information to diverse audiences. When communicating technical details, it’s crucial to first understand the audience’s level of technical expertise and tailor the message accordingly. Avoid jargon and technical terms that may not be familiar to the audience. Use clear and concise language, and break down complex concepts into smaller, more manageable pieces. Visual aids, such as diagrams, charts, and graphs, can be helpful for illustrating technical information. Provide context and explain the relevance of the information to the audience’s interests and needs. Encourage questions and provide thoughtful and informative answers. Be mindful of cultural differences and communication styles, and adapt the message accordingly. When communicating with patients, it’s essential to use plain language and avoid medical jargon. Provide information about the benefits and risks of medications in a clear and understandable manner. Be empathetic and responsive to patients’ concerns and questions. Throughout the communication process, maintain a commitment to accuracy and transparency. Verify the accuracy of the information before sharing it, and be honest about any limitations or uncertainties.

The most effective approach is to prioritize open communication, active listening, and empathy. This involves creating a safe space for employees to share their concerns and perspectives, actively listening to their feedback, and demonstrating empathy for their experiences. It also involves taking concrete steps to address the issues raised by employees and create a more inclusive and equitable work environment. Ignoring employee concerns or dismissing them as unimportant can damage morale and undermine trust. Punishing employees for speaking out can create a culture of fear and silence. Focusing solely on diversity metrics without addressing the underlying issues of inclusion and equity is insufficient. The goal is to create a workplace where all employees feel valued, respected, and empowered.

First show the complete calculation arriving at the exact final answer. Then write a detailed explanation of at least 150 words, very important do not mention option a,b,c,d in here as I will shuffle the options sequence